Your browser doesn't support javascript.
loading
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Noureddin, Mazen; Truong, Emily; Mayo, Rebeca; Martínez-Arranz, Ibon; Mincholé, Itziar; Banales, Jesus M; Arrese, Marco; Cusi, Kenneth; Arias-Loste, María Teresa; Bruha, Radan; Romero-Gómez, Manuel; Iruzubieta, Paula; Aller, Rocio; Ampuero, Javier; Calleja, José Luis; Ibañez-Samaniego, Luis; Aspichueta, Patricia; Martín-Duce, Antonio; Kushner, Tatyana; Ortiz, Pablo; Harrison, Stephen A; Anstee, Quentin M; Crespo, Javier; Mato, José M; Sanyal, Arun J.
Afiliación
  • Noureddin M; Houston Methodist Hospital, Houston Research Institute Houston, Texas, USA.
  • Truong E; Houston Research Institute, Houston, Texas, USA.
  • Mayo R; Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Martínez-Arranz I; OWL Metabolomics, Derio, Spain.
  • Mincholé I; OWL Metabolomics, Derio, Spain.
  • Banales JM; OWL Metabolomics, Derio, Spain.
  • Arrese M; Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV-EHU), CIBERehd, IKERBASQUE, Donostia, Spain.
  • Cusi K; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
  • Arias-Loste MT; Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Bruha R; University of Florida, Gainesville, Florida, USA.
  • Romero-Gómez M; Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain.
  • Iruzubieta P; General University Hospital and the First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Aller R; Valme University Hospital, CIBERehd, Seville, Spain.
  • Ampuero J; Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain.
  • Calleja JL; Clinic University Hospital, University of Valladolid, Valladolid, Spain.
  • Ibañez-Samaniego L; Virgen del Rocío University Hospital, Sevilla, Spain.
  • Aspichueta P; Puerta del Hierro University Hospital, Madrid, Spain.
  • Martín-Duce A; Gregorio Marañón University Hospital, Madrid, Spain.
  • Kushner T; Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
  • Ortiz P; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Harrison SA; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain.
  • Anstee QM; Príncipe de Asturias University Hospital, Alcalá University, Madrid, Spain.
  • Crespo J; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
  • Mato JM; OWL Metabolomics, Derio, Spain.
  • Sanyal AJ; Pinnacle Clinical Research, San Antonio, Texas, USA.
Hepatology ; 79(1): 135-148, 2024 Jan 01.
Article en En | MEDLINE | ID: mdl-37505221
BACKGROUND: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. METHODS: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). RESULTS: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE ( p = 0.69) to identify at-risk MASH. CONCLUSION: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diagnóstico por Imagen de Elasticidad / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diagnóstico por Imagen de Elasticidad / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos